COGNITE
In the midst of the largest industrial revolution, Cognite , a leader in industrial digitalization, announced the release of The Definitive Guide To Industrial DataOps . A first for the industry, the book defines and explains the emerging discipline of Industrial DataOps in language crafted for both business and IT professionals, while addressing the urgency driven by accelerating, data-driven shifts that modern organizations now navigate. The insights and industry expertise captured in the book also offer organizations practical advice on successful Industrial DataOps adoption and scaling. A request for proposal (RFP) guide, and a self-assessment to evaluate organizational readiness and map out challenges, round out the actionable insights and tools covered in the book.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211005005582/en/
Industrial DataOps is already becoming a driving force in industrial transformations, helping accelerate digital maturity, enabling data teams to deliver more digital products, and realizing more operational value at scale. In a 2020 survey of global companies, McKinsey found organizations that embedded DataOps could see the volume of new features increase by 50 percent because data automation enables quicker development iterations.
“Data trust comes from connecting the dots between desired outcomes and relevant use-case-oriented data products,” says Forrester VP, Principal Analyst Michele Goetz. “An Industrial DataOps platform brings context to data conditions and ensures business impacting data anomalies are caught early to mitigate costly issues. A DataOps platform also ensures data complies with data models and output standards to drive results from event-based intelligence inside processes.”
‘The Definitive Guide to Industrial DataOps’ was written to de-hype industrial digitalization and to help make sense of how Industrial DataOps allows organizations to manage complex data. The book’s structure reflects the journey that industrial companies will take as they evaluate, adopt, and scale Industrial DataOps across their organizations. The early chapters cover the urgency of Industrial DataOps and get readers to take stock of their industrial organizations’ digital maturity. The core chapters address the discipline itself, its key principles, and how to best extract value from data, while the final chapters define the way forward: scaling Industrial DataOps and putting it into practice.
“Industrial DataOps is a crucial and necessary tool to make digital transformation possible in asset-intensive industries,” says John Markus Lervik, CEO and co-founder of Cognite. “It illustrates how to connect data from the IT and OT source to the data consumer with contextual tips that will empower organizations of all sizes to use it, innovate off of it, and reshape operations for efficiency, profitability, and sustainability. It is the strongest driver of change that will propel the industry forward, and this book will help companies as they navigate their way and capture immediate value at scale.”
“To make the promise of Industrial DataOps a reality for enterprises, ´The Definitive Guide to Industrial DataOps´ serves as a critical manual to not only understand this novel software category, but as well how it accelerates innovation and reduces time-to-value at each stage of a digital operations transformation,” says Pascal Brosset, Industry X Production & Operations Lead at Accenture.
The full book is available for download for free: The Definitive Guide To Industrial DataOps
About Cognite
Cognite is a global industrial SaaS company that was established with one clear vision: to rapidly empower industrial companies with contextualized, trustworthy, and accessible data to help drive the full-scale digital transformation of asset-intensive industries around the world. Our core Industrial DataOps platform, Cognite Data Fusion™, enables industrial data and domain users to collaborate quickly and safely to develop, operationalize, and scale industrial AI solutions and applications to deliver both profitability and sustainability. Visit us at www.cognite.com and follow us on Twitter @CogniteData or LinkedIn: https://www.linkedin.com/company/cognitedata .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005582/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom